Luteolin is effective in the non‐small cell lung cancer model with<scp>L</scp>858<scp>R</scp>/<scp>T</scp>790<scp>M EGF</scp>receptor mutation and erlotinib resistance

Abstract

Luteolin may be a potential candidate for NSCLC therapy, especially for treatment of patients with acquired erlotinib-resistant NSCLC.